The effect of remifentanil intranasal on hemodynamic changes induced by electroconvulsive therapy

Phase 3

Recruiting

• Conditions: Y84.3; Electroshock therapy.; Shock therapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

• Registration Number: IRCT20200825048515N20
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Aged over 18 years
Candidates for electroconvulsive therapy for the first time
Classified as ASA I based on American Society of Anesthesiologists Classification
No fever
Consent to participate in the study

Exclusion Criteria

Allergy to remifentanil
History of nasal-related diseases that interfere with intranasal drug administration

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Heart rate. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Oxygen saturation. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.;Duration of convulsion. Timepoint: 1, 5, 10, and 20 minutes after the end of the convulsion. Method of measurement: Monitoring device.